Literature DB >> 30948892

Gynecological Cancers-the Changing Paradigm.

P Rema1.   

Abstract

Outstanding research in the last few decades led to newer insights into the management of gynecological cancers. In the preventive arena, the efficacy and safety of HPV vaccination are well accepted and is now in addition to bi- and quadrivalent vaccines; there is a nonavalent vaccine against nine oncogenic HPV strains. Recent studies also looked into the dosaging schedules and age of vaccination against HPV to improve the vaccine efficacy and coverage. HPV testing is now approved as a primary screening test for cervical cancer in women aged more than 30 years with better sensitivity than the traditional cytology. Opportunistic salpingectomy for ovarian cancer prevention and neoadjuvant chemotherapy for advanced ovarian cancers are accepted practices. The role of personalized medicine in ovarian cancer and comprehensive genomic analysis of endometrial cancers are also covered in this review.

Entities:  

Keywords:  Gynecological cancers; HPV vaccination; Molecular characterization endometrial cancers; Personalized treatment

Year:  2018        PMID: 30948892      PMCID: PMC6414572          DOI: 10.1007/s13193-018-0842-7

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  63 in total

1.  Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.

Authors:  Diane M Harper; Eduardo L Franco; Cosette M Wheeler; Anna-Barbara Moscicki; Barbara Romanowski; Cecilia M Roteli-Martins; David Jenkins; Anne Schuind; Sue Ann Costa Clemens; Gary Dubin
Journal:  Lancet       Date:  2006-04-15       Impact factor: 79.321

2.  Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

Authors:  Deborah K Armstrong; Brian Bundy; Lari Wenzel; Helen Q Huang; Rebecca Baergen; Shashikant Lele; Larry J Copeland; Joan L Walker; Robert A Burger
Journal:  N Engl J Med       Date:  2006-01-05       Impact factor: 91.245

3.  A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China.

Authors:  You-Lin Qiao; John W Sellors; Paul S Eder; Yan-Ping Bao; Jeanette M Lim; Fang-Hui Zhao; Bernhard Weigl; Wen-Hua Zhang; Roger B Peck; Ling Li; Feng Chen; Qing-Jing Pan; Attila T Lorincz
Journal:  Lancet Oncol       Date:  2008-09-19       Impact factor: 41.316

4.  Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma.

Authors:  Anna Fagotti; Gabriella Ferrandina; Francesco Fanfani; Giorgia Garganese; Giuseppe Vizzielli; Vito Carone; Maria Giovanna Salerno; Giovanni Scambia
Journal:  Am J Obstet Gynecol       Date:  2008-09-17       Impact factor: 8.661

5.  Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.

Authors:  R E Bristow; F J Montz; L D Lagasse; R S Leuchter; B Y Karlan
Journal:  Gynecol Oncol       Date:  1999-03       Impact factor: 5.482

6.  Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group.

Authors:  M Markman; B N Bundy; D S Alberts; J M Fowler; D L Clark-Pearson; L F Carson; S Wadler; J Sickel
Journal:  J Clin Oncol       Date:  2001-02-15       Impact factor: 44.544

7.  Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.

Authors:  Timothy R Rebbeck; Henry T Lynch; Susan L Neuhausen; Steven A Narod; Laura Van't Veer; Judy E Garber; Gareth Evans; Claudine Isaacs; Mary B Daly; Ellen Matloff; Olufunmilayo I Olopade; Barbara L Weber
Journal:  N Engl J Med       Date:  2002-05-20       Impact factor: 91.245

Review 8.  Cervical cancer screening: from the Papanicolaou smear to the vaccine era.

Authors:  Christopher P Crum; Derek W Abbott; Bradley J Quade
Journal:  J Clin Oncol       Date:  2003-05-15       Impact factor: 44.544

9.  Human papillomavirus and Papanicolaou tests to screen for cervical cancer.

Authors:  Pontus Naucler; Walter Ryd; Sven Törnberg; Anders Strand; Göran Wadell; Kristina Elfgren; Thomas Rådberg; Björn Strander; Bo Johansson; Ola Forslund; Bengt-Göran Hansson; Eva Rylander; Joakim Dillner
Journal:  N Engl J Med       Date:  2007-10-18       Impact factor: 91.245

10.  Rationale for folate receptor alpha targeted therapy in "high risk" endometrial carcinomas.

Authors:  Monica Brown Jones; Christina Neuper; Amy Clayton; Andrea Mariani; Gottfried Konecny; M Bijoy Thomas; Gary Keeney; Lynn Hartmann; Karl C Podratz
Journal:  Int J Cancer       Date:  2008-10-01       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.